Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bexxar Therapeutic Regimen, anti-B1 Antibody
Iodine I 131 Tositumomab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Iodine I 131 Tositumomab | DRUG | - |
Inclusion Criteria: * At least 18 years of age * Histologically confirmed diagnosis of follicular lymphoma, Grade 1, 2, or 3, or diffuse large cell lymphoma (WHO/REAL classification). Follicular, small cleaved; Follicular, mixed small cleaved and large cell; Follicular large cell lymphoma Transfor...
Iodine I 131 Tositumomab is an investigational monoclonal antibody-based oncology therapy being developed by GSK plc for Non-Hodgkin's Lymphoma. It combines a monoclonal antibody with the radioisotope iodine I 131. It is in Phase 1 clinical development and is not approved for commercial use.
Iodine I 131 Tositumomab is being studied for the treatment of Non-Hodgkin's Lymphoma, specifically in patients with untreated or transformed follicular Non-Hodgkin's Lymphoma. The only recorded clinical trial enrolled adults 18 years and older in the United States. It remains an investigational agent in Phase 1 development.
GSK plc, which trades under the ticker GSK, is the developer of Iodine I 131 Tositumomab. The company is responsible for the clinical program evaluating the agent in Non-Hodgkin's Lymphoma. No other developer or partnership is associated with this asset in the available program information.
Iodine I 131 Tositumomab is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The program has one completed Phase 1 trial and no active trials, with a total reported enrollment of 12 patients.
Iodine I 131 Tositumomab has been evaluated in one clinical trial, NCT00062894, titled Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab. That Phase 1 trial is completed, enrolled 12 patients in the United States, was uncontrolled, and was not randomized or double blinded.